|
Search
Collections
Benchmarks
Upload document
Product
F16IL2
Rename entity
Add alias
Merge entity
Delete entity
Embed entity
1 clinical trial
3 indications
Indication
Acute Myeloid Leukemia
Indication
Relapsed
Indication
Adult
Clinical trial
A Dose-finding Phase I Study of the Tumor-targeting Human F16IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With Very Low-dose Cytarabine in Patients With AML Relapse After Allogeneic Hematopoietic Stem Cell Transplantation
Status: Terminated
, Estimated PCD: 2023-09-29
